Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

M. Wislez; C. Mascaux; J. Cadranel; Q.D. Thomas; C. Ricordel; A. Swalduz; E. Pichon; R. Veillon; V. Gounant; G. Rousseau-Bussac; A. Madroszyk; C. Daniel; M. Ravoire; A.-C. Metivier; P. Fournel; P. Missy; F. Morin; F. Guisier; V. Westeel

doi:10.1016/j.ejca.2025.115301

journal article Open Access Mar 01, 2025

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

M. Wislez C. Mascaux J. Cadranel Q.D. Thomas C. Ricordel A. Swalduz E. Pichon R. Veillon V. Gounant G. Rousseau-Bussac A. Madroszyk C. Daniel M. Ravoire A.-C. Metivier P. Fournel P. Missy F. Morin F. Guisier V. Westeel

European Journal of Cancer Vol. 219 pp. 115301 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2025.115301

Topics

No keywords indexed for this article. Browse by subject →

References

23

[1]

Alharbi "CodeBreak 200: study limitations, and future directions" Transl Cancer Res (2024) 10.21037/tcr-23-1477

[2]

Araghi "Recent advances in non-small cell lung cancer targeted therapy; an update review" Cancer Cell Int (2023) 10.1186/s12935-023-02990-y

[3]

Chour "Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer" J Thorac Oncol: Publ Int Assoc Study Lung Cancer, mai (2023)

[4]

« Demande d’autorisation d’accès précoce ». s. d. ANSM. Consulté le 13 septembre 2024. https://ansm.sante.fr/vos-demarches/industriel/demande-dautorisation-dacces-precoce.

[5]

Desai "Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: a brief report" Cancer Treat Res Commun (2023)

[6]

Dy "Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100" J Clin Oncol: J Am Soc Clin Oncol (2023) 10.1200/jco.22.02524

[7]

Ernst "Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis" EBioMedicine (2024)

[8]

Fatima "KRAS as a prognostic and predictive marker in metastatic non-small cell lung carcinoma: a systematic review" Cureus (2024)

[9]

Kelly "Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?" Lung Cancer (1998) 10.1016/s0169-5002(98)00020-8

[10]

Langen "Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial" Lancet (Lond, Engl) (2023) 10.1016/s0140-6736(23)00221-0

[11]

Li "OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC" J Thorac Oncol, Abstr 2022 World Conf Lung Cancer (2022)

[12]

Lombardi "Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature" Cancer Treat Rev (2014) 10.1016/j.ctrv.2014.05.007

[13]

Ostrem "Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design" Nat Rev Drug Discov (2016) 10.1038/nrd.2016.139

[14]

Passiglia "Sotorasib in KRASp.G12C mutated advanced NSCLC: real-world data from the italian expanded access program" Lung Cancer (2024) 10.1016/j.lungcan.2023.107444

[15]

Sehgal "Association of performance status with survival in patients with advanced non–small cell lung cancer treated with pembrolizumab monotherapy" JAMA Netw Open (2021) 10.1001/jamanetworkopen.2020.37120

[16]

Siegel "Cancer Statistics, 2023" CA: A Cancer J Clin (2023)

[17]

Skoulidis "Sotorasib for lung cancers with KRAS p.G12C mutation" N Engl J Med (2021) 10.1056/nejmoa2103695

[18]

Staff. 2021. « Further Analyses Expand Upon Duration of Benefit With Sotorasib in KRAS G12C+ NSCLC », Targeted Therapies in Oncology, 10 (octobre). https://www.targetedonc.com/view/further-analyses-expand-upon-duration-of-benefit-with-sotorasib-in-kras-g12c-nsclc.

[19]

———. 2024. « Experts Examine the Need for Targeted Therapy Options for KRAS G12C–Mutated NSCLC » , Oncology, 38 (février):15‑17.

[20]

Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany

Jan A. Stratmann, Friederike C. Althoff, Paula Doebel et al.

European Journal of Cancer 2024 10.1016/j.ejca.2024.113911

[21]

Thomas "Clinical Characteristic and Survival Outcomes of Patients with Advanced NSCLC According to KRAS Mutational Status in the French Real-Life ESME Cohort" ESMO Open (2024) 10.1016/j.esmoop.2024.103473

[22]

Thummalapalli "Clinical and genomic features of response and toxicity to sotorasib in a real-world cohort of patients with advanced KRAS G12C-mutant non-small cell lung cancer" JCO Precis Oncol (2023)

[23]

Ying "The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer" Transl Cancer Res (2024) 10.21037/tcr-23-2232

Metrics

3

Citations

23

References

Details

Published: Mar 01, 2025
Vol/Issue: 219
Pages: 115301
License: View

Authors

Cite This Article

M. Wislez, C. Mascaux, J. Cadranel, et al. (2025). Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. European Journal of Cancer, 219, 115301. https://doi.org/10.1016/j.ejca.2025.115301

Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study

You May Also Like